Live Typhoid and Yellow Fever Vaccines Administered to a Patient With Ulcerative Colitis on Vedolizumab

Overview

Journal ACG Case Rep J

Date 2025 Jan 27

PMID 39866528

Authors

Yash Hegde

Mary S Hayney

Freddy Caldera

Affiliations

Soon will be listed here.

Abstract

Patients with inflammatory bowel disease who receive immunosuppressive therapy have an increased risk of infection. Live vaccines are contraindicated in these patients because of the increased risk of unchecked replication of the attenuated vaccine microorganisms. Vedolizumab is a gut-selective biological agent with a low risk of infection approved for the treatment of inflammatory bowel disease. There are limited data on the risk of providing a live vaccine in patients receiving vedolizumab, and patients may receive live vaccines if the benefits outweigh the risks. We describe a patient with ulcerative colitis, treated with vedolizumab who received 2 live vaccines, typhoid and yellow fever, without postimmunization adverse events.

References

Ruddel J, Schleenvoigt B, Schuler E, Schmidt C, Pletz M, Stallmach A . Yellow fever vaccination during treatment with infliximab in a patient with ulcerative colitis: A case report. Z Gastroenterol. 2016; 54(9):1081-4. DOI: 10.1055/s-0042-109871. View

Marin M, Guris D, Chaves S, Schmid S, Seward J . Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-4):1-40. View

Colombel J, Sands B, Rutgeerts P, Sandborn W, Danese S, DHaens G . The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2016; 66(5):839-851. PMC: 5531223. DOI: 10.1136/gutjnl-2015-311079. View

DeBruyn J, Fonseca K, Ghosh S, Panaccione R, Gasia M, Ueno A . Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial. Inflamm Bowel Dis. 2015; 22(3):638-47. DOI: 10.1097/MIB.0000000000000615. View

Caldera F, Hayney M, Farraye F . Vaccination in Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2020; 115(9):1356-1361. DOI: 10.14309/ajg.0000000000000713. View

Rubin D, Ananthakrishnan A, Siegel C, Sauer B, Long M . ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019; 114(3):384-413. DOI: 10.14309/ajg.0000000000000152. View

Feagan B, Rutgeerts P, Sands B, Hanauer S, Colombel J, Sandborn W . Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369(8):699-710. DOI: 10.1056/NEJMoa1215734. View

McLean H, Parker Fiebelkorn A, Temte J, Wallace G . Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013; 62(RR-04):1-34. View

Ekenberg C, Friis-Moller N, Ulstrup T, Aalykke C . Inadvertent yellow fever vaccination of a patient with Crohn's disease treated with infliximab and methotrexate. BMJ Case Rep. 2016; 2016. PMC: 5015127. DOI: 10.1136/bcr-2016-215403. View

10.

Wichmann A, Krugliak Cleveland N, Rubin D . Safety and Efficacy of Live Measles Vaccine Administered to a Crohn's Disease Patient Receiving Vedolizumab. Am J Gastroenterol. 2016; 111(4):577. DOI: 10.1038/ajg.2016.21. View

11.

Croce E, Hatz C, Jonker E, Visser L, Jaeger V, Buhler S . Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and.... Vaccine. 2017; 35(9):1216-1226. DOI: 10.1016/j.vaccine.2017.01.048. View

12.

Farraye F, Melmed G, Lichtenstein G, Kane S . ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017; 112(2):241-258. DOI: 10.1038/ajg.2016.537. View

13.

Shiga H, Nagai H, Shimoyama Y, Naito T, Moroi R, Kakuta Y . Live-attenuated vaccination in patients with inflammatory bowel disease while continuing or after elective switch to vedolizumab. Intest Res. 2024; 22(3):378-386. PMC: 11309819. DOI: 10.5217/ir.2023.00203. View

14.

Sandborn W, Feagan B, Rutgeerts P, Hanauer S, Colombel J, Sands B . Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013; 369(8):711-21. DOI: 10.1056/NEJMoa1215739. View